晚期肝细胞癌的个性化综合治疗 (ICT-HCC)
探索性队列研究和关于高级肝细胞癌标准治疗后个性化综合治疗的机理研究
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Chen Xun
- 电话号码:+86-13851670770
- 邮箱:mxrlwx19911990@163.com
学习地点
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210000
- 招聘中
- China Pharmaceutical University Affiliated Nanjing Tianyinshan Hospital
-
接触:
- Chen Xun
- 电话号码:+86-13851670770
- 邮箱:mxrlwx19911990@163.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥18 years old, male or female
- Hepatocellular carcinoma patients diagnosed by cytology or tissue puncture, or who meet clinical diagnostic criteria and cannot be treated with radical treatment (radical surgery, ablation, radiotherapy, etc.)
- Clinical disease progression after first-line targeted combined immune system therapy (PD-1 or PD-L1 monoclonal antibody only)
- Life expectancy exceeds 3 months
- ECOG physical condition score 0~1
- Women of childbearing age must have a serum pregnancy study done within 7 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must consent to contraception within 24 weeks from the date of signing the informed consent to the last administration of the study drug
- Before the first dose of the investigational drug, the laboratory test values met the following conditions: ①blood routine (no blood transfusion within 14 days before screening, no hematopoietic stimulating drug correction) : white blood cell count (WBC) ≥ 2.0 × 109/L; platelet (PLT) ≥ 60× 109/L; hemoglobin content (HGB) ≥ 8.0 g/dL; ② Liver function: aspartate transferase (AST) ≤ 2.5x ULN; alanine aminotransferase (ALT) ≤ 2.5 x ULN; Serum total bilirubin (TBIL) ≤ 1.5 x ULN (except Gilbert syndrome total bilirubin ≤ 3.0 mg/dL); ③ Renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance rate (CrCl) ≥ 50 mL/minute; ④ Coagulation function: international normalized ratio (INR) ≤ 1.5 x ULN, activated partial thromboplastin time (APTT) ≤ 1.5 x ULN (only for patients who are not currently receiving anticoagulant therapy, patients who are currently receiving anticoagulant therapy should receive a steady dose of anticoagulant therapy)
- The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up
Exclusion Criteria:
- Pathological types of other non-hepatocellular carcinomas, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc. previously confirmed by histology/cytology
- Child-Pugh grade of liver function> 7 points
- Major cardiovascular impairment in the 6 months prior to initial administration of the drug, such as a New York Heart Association (NYHA) Class II or higher history of congestive heart failure, unstable angina, myocardial infarction or stroke, or arrhythmia associated with hemodynamic instability; Corrected QT (QTc) interval lengthening >480ms
- Other malignancies developed ≤ 5 years before the first dose, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery (hormone therapy for non-metastatic prostate cancer or breast cancer is allowed)
- Have had an active autoimmune disease in the past 2 years that requires systemic treatment, including but not limited to autoimmune hepatitis, lupus erythematosus, etc
- Uncontrolled active infection, such as active tuberculosis, HIV infection, etc.; Patients with HBV-DNA replication level below 10000IU/mL and continuous oral antiviral therapy could be enrolled.
- Had undergone major surgery in the 28 days prior to randomization or planned to undergo major surgery during the study period
- Use of live attenuated vaccine within 28 days prior to randomization, or anticipated use of such live attenuated vaccine during the study period (patients are not allowed to receive live attenuated influenza vaccine 4 weeks prior to randomization, during treatment, and within 5 months after the final administration of adbelizumab)
- Received any other investigational drug treatment or participated in another interventional clinical study within 4 weeks prior to signing the ICF
- Use of corticosteroids (> 10 mg/ day prednisone or equivalent dose) or other immunosuppressants within ≤ 14 days prior to the first dose of the study drug. Allowing inhaled or topical use of steroids and adrenal replacement steroids in the absence of active autoimmune disease; Patients received systemic immunosuppressive drugs (including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] drugs) within 1 week prior to randomization. Patients receiving short-term, systemic immunosuppressant therapy, such as glucocorticoids for nausea, vomiting, or anaphylaxis management or prevention, may be enrolled in the study after investigator review. To allow the use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease, corticosteroids such as fluhydrocortisone in patients with postural hypotension, and low-dose glucocorticoid supplements for adrenal insufficiency; Known mental illness, alcoholism, inability to quit smoking, drug or substance abuse
- In the investigator's judgment, the subjects have other factors that may lead to the forced termination of the study, such as non-compliance with the protocol, other serious illnesses (including mental illness) requiring combined treatment, serious laboratory abnormalities, family or social factors that may affect the safety of the subjects, or the collection of data and samples
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1
XELOX/FOLFOX4+ Adebelizumab + Apatinib+Icaritin |
FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles Adebrelimab 1200mg, intravenous infusion, every 3 weeks |
|
实验性的:Arm 2
Adebelizumab + Apatinib+Icaritin |
Adebrelimab 1200mg, intravenous infusion, every 3 weeks Apatinib 250mg, oral, once daily. Epimedium extract soft capsules 2.4g, oral, 2 times daily. |
|
实验性的:Arm 3a
QL1706+ Apatinib+Icaritin |
Apatinib 250mg, oral, once daily. Epimedium extract soft capsules 2.4g, oral, 2 times daily. QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most. |
|
实验性的:Arm 3b
Retlirafusp alfa+ Apatinib+Icaritin |
Apatinib 250mg, oral, once daily. Epimedium extract soft capsules 2.4g, oral, 2 times daily. Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most. |
|
实验性的:Arm 4
The original targeted combination immunotherapy+HAIC |
Apatinib 250mg, oral, once daily. Epimedium extract soft capsules 2.4g, oral, 2 times daily. QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most. Hepatic Arterial Infusion Chemotherapy Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before. |
|
实验性的:Arm 5a
QL1706+ Apatinib+Icaritin |
Apatinib 250mg, oral, once daily. Epimedium extract soft capsules 2.4g, oral, 2 times daily. QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most. |
|
实验性的:Arm 5b
Retlirafusp alfa+ Apatinib+Icaritin |
Apatinib 250mg, oral, once daily. Epimedium extract soft capsules 2.4g, oral, 2 times daily. Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most. |
|
实验性的:Arm 6a
QL1706+Bevacizumab+Icaritin |
Epimedium extract soft capsules 2.4g, oral, 2 times daily. QL1706,5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most. Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks. |
|
实验性的:Arm 6b
Retlirafusp alfa+Bevacizumab+Icaritin |
Epimedium extract soft capsules 2.4g, oral, 2 times daily. Retlirafusp alfa,1800mg, intravenous infusion, every 3 weeks, use for up to 2 years at most. Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PFS(Progression-free Survival)
大体时间:24 months
|
Progression-free survival (PFS) was defined as the time from treatment initiation on Day 1 to the earliest occurrence of radiologically confirmed disease progression, as assessed by tumor imaging, or death from any cause, whichever came first. Evaluations were conducted by the investigator in accordance with RECIST v1.1. |
24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
OS(Overall survival)
大体时间:48 months
|
Overall survival (OS) was defined as the duration from treatment initiation on Day 1 to death from any cause. |
48 months
|
|
ORR(Objective response rate)
大体时间:24 months
|
Objective response rate (ORR) was defined as the proportion of subjects achieving a complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1. |
24 months
|
|
DCR(Disease control rate )
大体时间:24 months
|
Disease control rate (DCR) was defined as the proportion of subjects achieving a complete response (CR), partial response (PR), or stable disease (SD) lasting ≥8 weeks, as assessed by the investigator according to RECIST v1.1, from the initiation of treatment on Day 1. |
24 months
|
|
DOR(Duration of Response)
大体时间:24 months
|
Duration of response (DOR) was defined as the time from the first documented objective response (CR or PR) to the earliest occurrence of radiological disease progression or death from any cause, whichever occurred first. Both response and progression were evaluated by the investigator according to RECIST v1.1. |
24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.